Dare Bioscience Q1 cash $19.8M; Sildenafil Cream Phase 2b data and XACIATO launch expected Q2

Dare Bioscience, Inc.

2023-Q1 EPS reported -$0.09

Cash $19.8M at March 31; G&A $3.3M (up from $2.6M) on commercial-readiness and email fraud loss; R&D $5.0M (down from $5.8M).
Expects Sildenafil Cream Phase 2b topline data in Q2 2023 for FSAD, a condition with no FDA-approved treatments.
XACIATO first commercial sale by Organon expected Q2 2023, triggering $2.5M milestone payment to Daré.
Ovaprene pivotal Phase 3 contraceptive study start mid-2023 under NIH/NICHD CRADA; DARE-HRT1 and DARE-VVA1 IND prep ongoing.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Dare Bioscience, Inc. reported financial results for first fiscal quarter ended March 31, 2023.

Period: first fiscal quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Dare Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016287

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.